OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

Rhea-AI Summary

OSR Holdings (NASDAQ:OSRH) completed the acquisition of Woori IO, effective January 26, 2026, making Woori IO a consolidated subsidiary and strengthening OSRH's noninvasive glucose monitoring and wearable health capabilities.

Legacy shareholders of Woori IO agreed to a three-year equity alignment to exchange OSR Holdings Co., Ltd. (OSRK) interests into NASDAQ-listed OSRH common stock only at a USD $10.00 per share reference price, intended to limit near-term dilution. OSRH also initiated a strategic review to potentially combine its medical device subsidiaries, Woori IO and RMC, to form an integrated medical technology and distribution company and evaluate a possible standalone IPO in Korea, subject to market, regulatory, and board approvals.

Positive

• Acquisition of Woori IO closed effective Jan 26, 2026
• Three-year equity alignment at reference price of $10.00 to limit near-term dilution
• Adds noninvasive glucose monitoring and wearable health capabilities
• Strategic review could enable a combined platform and potential Korean IPO

Negative

• Standalone IPO is conditional on market conditions, regulatory approval, and board consent
• Equity alignment fixes conversion at $10.00, delaying potential liquidity at other prices

Key Figures

Reference share price: $10.00 per share Equity alignment term: 3 years Medical device subsidiaries: 2 subsidiaries

3 metrics

Reference share price $10.00 per share Exchange into NASDAQ-listed OSRH common stock

Equity alignment term 3 years Three-year equity alignment framework for legacy Woori IO shareholders

Medical device subsidiaries 2 subsidiaries Potential combination of Woori IO and RMC

Market Reality Check

Price: $0.6920 Vol: Volume 814,114 vs 20-day ...

low vol

$0.6920 Last Close

Volume Volume 814,114 vs 20-day average 3,051,327 suggests muted trading interest into this news. low

Technical Shares at $0.72 are trading below the $0.89 200-day moving average and far under the $10.00 52-week high.

Peers on Argus

OSRH was down 10.94% while peers showed mixed moves: ADAP (-17.57%), APLM (+3.83...

1 Up

OSRH was down 10.94% while peers showed mixed moves: ADAP (-17.57%), APLM (+3.83%), APM (-2.34%), PHGE (+3.80%), PHIO (-4.59%). This points to stock-specific dynamics rather than a synchronized sector rotation.

Previous Acquisition Reports

2 past events · Latest: Oct 14 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Oct 14	Definitive acquisition deal	Positive	-3.0%	Definitive agreement to acquire Woori IO and outline contingent OSRH share conversion.
Jul 24	Acquisition term sheet	Positive	-5.9%	Initial term sheet to acquire Woori IO with contingent OSRH share conversion terms.

Pattern Detected

Past Woori IO acquisition headlines were strategically positive but saw negative next-day moves, indicating a pattern of selling into this news type.

Recent Company History

Over the last six months, OSR Holdings has repeatedly highlighted the Woori IO acquisition, from an initial term sheet on Jul 24, 2025 to a definitive agreement on Oct 14, 2025. Both prior acquisition announcements focused on noninvasive glucose monitoring technology and potential share conversion at $10, yet the stock declined 5.88% and 3.01% the following days. Today’s closing and alignment update extend that same strategic arc, reinforcing the long-term Woori IO thesis despite weak price reactions.

Historical Comparison

acquisition

+4.5 %

Average Historical Move

Historical Analysis

Past Woori IO acquisition headlines (term sheet and definitive deal) averaged a 4.45% move, both skewing negative despite constructive strategic framing.

Typical Pattern

Progression from acquisition term sheet to definitive agreement and now formal closing of the Woori IO transaction.

Market Pulse Summary

This announcement closes the Woori IO acquisition, secures a three-year equity alignment at a $10.00...

Analysis

This announcement closes the Woori IO acquisition, secures a three-year equity alignment at a $10.00 reference price, and launches a review to combine Woori IO and RMC into an integrated medtech platform. In context of prior term sheet and definitive agreement news, it marks the completion of a multi-stage transaction. Investors may track integration milestones, any concrete steps toward a Korean IPO, and how these moves interact with existing operating losses and Nasdaq compliance considerations.

Key Terms

noninvasive glucose monitoring, digital health, ipo

3 terms

noninvasive glucose monitoring medical

"particularly in noninvasive glucose monitoring and wearable health technologies."

A method or device that measures a person’s blood sugar level without piercing the skin or drawing blood, typically using external sensors or light-based techniques. For investors, it matters because successful noninvasive monitoring could unlock a large consumer and medical market by making glucose checks easier, cheaper and more frequent—similar to checking tire pressure without removing the cap—affecting sales, adoption rates and regulatory risk for companies developing the technology.

digital health medical

"strengthening the Company's medical device and digital health platform,"

Digital health involves the use of technology, such as apps, wearable devices, and online platforms, to monitor, manage, and improve people's health and healthcare. For investors, it represents a growing industry that combines healthcare with digital innovation, offering new ways to deliver medical services and track wellness, which can lead to advancements in patient care and potential business opportunities.

ipo financial

"could support a standalone IPO in Korea, subject to market conditions,"

An initial public offering (IPO) is the process by which a private company sells its shares to the public for the first time, making its ownership available on the stock market. This allows the company to raise money from a wide range of investors to fund growth or other goals. For investors, an IPO offers a chance to buy into a company early in its public journey, potentially benefiting if the company grows in value.

AI-generated analysis. Not financial advice.

BELLEVUE, WA / ACCESS Newswire / January 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment by Woori IO's historical shareholders, and the initiation of a strategic review regarding a potential combination of its medical device subsidiaries.

Woori IO Acquisition Closed

OSRH confirmed that the previously announced acquisition of Woori IO and the related share exchange transaction have been formally completed in Korea, effective January 26, 2026. As a result, Woori IO is now a consolidated subsidiary of OSRH, further strengthening the Company's medical device and digital health platform, particularly in noninvasive glucose monitoring and wearable health technologies.

Three-Year Equity Alignment Secured by Legacy Shareholder

In connection with the closing, historical shareholders of Woori IO reaffirmed a three-year equity alignment framework, under which they have agreed to exchange their equity interests in OSR Holdings Co., Ltd. (OSRK) into NASDAQ-listed OSRH common stock only at a reference price of USD $10.00 per share. This voluntary structure is designed to prevent near-term dilution and align legacy shareholders with the long-term performance of OSRH's public equity, reflecting confidence in the Company's strategic direction and capital markets positioning.

Strategic Review of Medical Device Subsidiaries

Separately, Peter Hwang, CEO of OSRH, indicated that the Company is conducting a strategic review of a potential combination of its two medical device subsidiaries, Woori IO and RMC, with the goal of forming a new, integrated medical technology and distribution company.

The review reflects the complementary strengths of the two businesses, including Woori IO's digital health and wearable-device capabilities, supported by collaboration initiatives with Samsung Electronics, along with RMC's established hospital network in Korea and commercial revenue history. OSRH is evaluating whether a combined platform could support a standalone IPO in Korea, subject to market conditions, regulatory considerations, and board approvals.

Positioned for Continued Value Creation

"With the Woori IO acquisition now closed, long-term alignment secured from legacy shareholders, and a strategic review underway to unlock synergies across our medical device businesses, we believe OSR Holdings is well positioned to pursue multiple, disciplined pathways to value creation," said Mr. Hwang.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected benefits of the Woori IO acquisition, shareholder alignment, potential strategic transactions, and future business plans. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially, including regulatory, integration, market, execution, and capital markets risks, as well as other risks described in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

About OSR Holdings, Inc.

OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device technologies. Its vision is to build a portfolio of breakthrough healthcare solutions to improve global health outcomes. Learn more at www.OSR-Holdings.com.

About Woori IO Co., Ltd.

Woori IO is a South Korea-based medical device company developing noninvasive biosensing technologies for glucose monitoring and beyond. Its proprietary NIRS-based system enables accurate, pain-free glucose tracking and is designed for integration into wearables. The company has been recognized by a leading global consumer electronics company's startup program for its innovation in NIGM technology.

CONTACT:

Media & Investor Contacts
OSR Holdings, Inc.
Investor Relations
ir@osr-holdings.com

SOURCE: OSR Holdings, Inc.

View the original press release on ACCESS Newswire

FAQ

When did OSR Holdings (OSRH) complete the Woori IO acquisition?

The acquisition closed effective January 26, 2026, and Woori IO is now a consolidated subsidiary of OSRH.

What is the three-year equity alignment tied to Woori IO shareholders for OSRH (OSRH)?

Historical Woori IO shareholders agreed to exchange OSRK interests into NASDAQ-listed OSRH common stock only at a reference price of $10.00 per share for three years to limit near-term dilution.

What strategic review did OSR Holdings announce regarding its medical device units?

OSRH launched a strategic review to evaluate combining its medical device subsidiaries Woori IO and RMC into an integrated medical technology and distribution company.

Could the combined Woori IO and RMC platform lead to an IPO for OSRH assets?

OSRH is evaluating whether a combined platform could support a standalone IPO in Korea, subject to market conditions, regulatory considerations, and board approvals.

How does the Woori IO acquisition affect OSRH's product focus?

The acquisition strengthens OSRH's focus on noninvasive glucose monitoring and wearable health technologies, including collaborations supporting digital health capabilities.